

Attorney's Docket No.: U 012567-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Inventors:

- SUMAN PREET SINGH KHANUJA 1.
- 2. AJIT KUMAR SHASANY
- SUNITA DHAWAN З.
- MAHENDRA PANDURANG DAROKAR 4.
- 5. SARITA SATAPATHY
- 6. TIRUPPADIRIPULIYUR R. SANTHA KUMAR
- 7. DHARMENDRA SAIKIA
- 8. NIRMAL KUMAR PATRA
- 9. JANAK RAJ BAHL
- 10. ARUN KUMAR TRIPATHY
- 11. SUSHIL KUMAR

WARNING: The Declaration must name all of the actual inventor(s).

For (title):

A NOVEL SCREENING METHOD FOR SELECTION OF INSECT TOLERANT PLANTS

Type of Application 1.

This new application is for a(n) (check one applicable item below):

Original (nonprovisional)

prior to mailing. 37 CFR 1.10(b).

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date JANUARY 18, 2000 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL386267046US addressed to the: Assistant Commissioner of Patents, Washington, D.C. 20231

JENNIFER RASHKIN

type or print name of person mailing paper)

NOTE: Each paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon


WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 CFR 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

(Application Transmittal [4-1]—page 1 of 7)



		Daving					
	_	Design					
		Plant					
WARNING:		Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4) unless the International Application is being filed as a divisional, continuation or continuation-inpart application.					
WARNING:		Do not use this transmittal for the filing of a provisional application.					
2.	Bene	efit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)					
NOTE:	where applic	new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or a the parent case is an International Application which designated the U.S., or benefit of a prior provisional ation is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW ICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.					
WARNING:		If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the application should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.					
WARNING:		When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional must be filed prior to the Saturday, Sunday or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).					
		The new application being transmitted claims the benefit of prior U.S. application(s and enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.					
NOTE:	TRAN	e of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION ISMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT CATION OF THE FILING OF THIS CONTINUATION APPLICATION.					
		Divisional.					
		Continuation.					
		Continuation-in-Part (C-I-P).					
3.	1 15	rs Enclosed That Are Required For Filing Date Under 37 CFR 1.53 (Regular) or 37 CFR 3 (Design) Application					
	20	Pages of specification (no page 10)					
	2	Pages of claims					
	1	Pages of Abstract					
98		Sheets of drawing (2 SETS OF SHEETS 1-3)					
•	•	☑ formal					
		□ informal					
WARNI	NG:	DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a					

non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. Comments on proposed new 37 CFR 1.84. Notice of March 9, 1988 (1990 O.G. 57-62).



(complete the following, if applicable)

The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO
ACCEPT PHOTOGRAPH(S) AS DRAWING(S)". 37 C.F.R. 1.84(b).

Preliminary Amendment Information Disclosure Statement (37 CFR 1.98)										
Information Disclosure Statement (37 CFR 1.98) Form PTO-1449 Citations Declaration of Biological Deposit Submission of "Sequence Listing," computer readable copy and/or amendmental pertaining thereto for biotechnology invention containing nucleotide and/or aminor sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representate Special Comments Other Declaration or oath Enclosed executed by (check all applicable boxes) inventors. legal representative of inventors, 37 CFR 1.42 or 1.43 joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). Showing that the filing is authorized. (Not required unless called into quiton. 37 CFR 1.41(d).)	4.									
 □ Form PTO-1449 □ Citations □ Declaration of Biological Deposit □ Submission of "Sequence Listing," computer readable copy and/or amendmental pertaining thereto for biotechnology invention containing nucleotide and/or aminor sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representate Special Comments □ Other 5. Declaration or oath □ Enclosed executed by (check all applicable boxes) □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. ☑ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-inpart, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surchar required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into quetion. 37 CFR 1.41(d).) 		\square		·						
□ Citations □ Declaration of Biological Deposit □ Submission of "Sequence Listing," computer readable copy and/or amendmental pertaining thereto for biotechnology invention containing nucleotide and/or aminor sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representate Special Comments □ Other 5. Declaration or oath □ Enclosed □ executed by (check all applicable boxes) □ inventors. □ legal representative of inventors, 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be judicing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. □ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filled subsequently). NOTE: It is important that all the correct inventor(s) are named for filling under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filling is authorized. (Not required unless called into question. 37 CFR 1.41(d).)			Info	Information Disclosure Statement (37 CFR 1.98)						
 □ Declaration of Biological Deposit □ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or aminor sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representat □ Special Comments □ Other 5. Declaration or oath □ Enclosed executed by (check all applicable boxes) □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. ☑ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surche required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filling under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filling is authorized. (Not required unless called into question. 37 CFR 1.41(d).) 			Forn	n PT(O-1449					
□ Submission of "Sequence Listing," computer readable copy and/or amendmental pertaining thereto for biotechnology invention containing nucleotide and/or aminor sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representate Special Comments □ Other 5. Declaration or oath □ Enclosed executed by (check all applicable boxes) □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. □ Not Enclosed. WARNING: Where the filling is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subjection international Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. □ Application is made by a person authorized under 37 CFR 1.41(c) on behall all the above named inventors. (The declaration or oath, along with the surche required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into que tion. 37 CFR 1.41(d).)			Cita	tions						
pertaining thereto for biotechnology invention containing nucleotide and/or aminor sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representate Special Comments Other Declaration or oath Enclosed executed by (check all applicable boxes) inventors. legal representative of inventors. 37 CFR 1.42 or 1.43 joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. Not Enclosed. WARNING: Where the filling is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition the International Application the application may be treated as a continuation or continuation—part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surche required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventorial are named for filling under 37 CFR 1.41(c) and 1.53(b). Showing that the filling is authorized. (Not required unless called into que tion. 37 CFR 1.41(d).)			Dec	larati	on of Biological Deposit					
 □ Special Comments □ Other 5. Declaration or oath □ Enclosed executed by (check all applicable boxes) □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. ☑ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filled subsequently). NOTE: It is important that all the correct inventor(sl are named for filling under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filling is authorized. (Not required unless called into question. 37 CFR 1.41(d).) 			pert	aining	g thereto for biotechnology invention containing nucleotide and/or amino acid					
 □ Other 5. Declaration or oath □ Enclosed executed by (check all applicable boxes) □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. ☑ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject marter in addition to International Application the application may be rested as a continuation or continustion-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surche required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).) 			Autl	horiza	ation of Attorney(s) to Accept and Follow Instructions from Representative					
Enclosed executed by (check all applicable boxes) inventors. legal representative of inventors. 37 CFR 1.42 or 1.43 joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject marter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or and and in the surche required by 37 CFR 1.16(e) can be filled subsequently). NOTE: It is important that all the correct inventor(s) are named for filling under 37 CFR 1.41(c) and 1.53(b). Showing that the filling is authorized. (Not required unless called into que tion. 37 CFR 1.41(d).)			Spe	ecial Comments						
 □ Enclosed executed by (check all applicable boxes) □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. ☑ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behall all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).) 			Oth	er						
executed by (check all applicable boxes) inventors. legal representative of inventors. 37 CFR 1.42 or 1.43 joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surche required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). Showing that the filling is authorized. (Not required unless called into quetion. 37 CFR 1.41(d).)	5.	Dec	larati	on or	oath					
 □ inventors. □ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. ☑ Not Enclosed. ☑ Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filling under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filling is authorized. (Not required unless called into question. 37 CFR 1.41(d).) 			Encl	losed						
□ legal representative of inventors. 37 CFR 1.42 or 1.43 □ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. □ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. □ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)			exec	cuted	by (check all applicable boxes)					
□ joint inventor or person showing a proprietary interest on behalf of inventor or refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. □ Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. □ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surchar required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)				inve	entors.					
refused to sign or cannot be reached. □ This is the petition required by 37 CFR 1.47 and the statement required 37 CFR 1.47 is also attached. See item 13 below for fee. □ Not Enclosed. Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. □ Application is made by a person authorized under 37 CFR 1.41(c) on behall all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into quantum. 37 CFR 1.41(d).)				lega	representative of inventors. 37 CFR 1.42 or 1.43					
Not Enclosed. WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). □ Showing that the filing is authorized. (Not required unless called into quantion. 37 CFR 1.41(d).)										
 WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behall all the above named inventors. (The declaration or oath, along with the surcharequired by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). ☐ Showing that the filing is authorized. (Not required unless called into qualition. 37 CFR 1.41(d).) 					This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.					
available or where the completion of the U.S. application contains subject matter in addition to International Application the application may be treated as a continuation or continuation-in-part, as the may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR APPLICATION CLAIMED. ☑ Application is made by a person authorized under 37 CFR 1.41(c) on behal all the above named inventors. (The declaration or oath, along with the surcha required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). ☐ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)		\square	Not	Enclo	osed.					
all the above named inventors. (The declaration or oath, along with the surcha required by 37 CFR 1.16(e) can be filed subsequently). NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b). Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)	WARN	ING:	available or where the completion of the U.S. application contains subject matter in an International Application the application may be treated as a continuation or continuation-in-pai may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT O							
Showing that the filing is authorized. (Not required unless called into que tion. 37 CFR 1.41(d).)				all th	he above named inventors. (The declaration or oath, along with the surcharge					
tion. 37 CFR 1.41(d).)	NOTE:	It is i	mporta	ant tha	nt all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b).					
O Lovernot and the Contract					Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)					
6. Inventorship Statement	6.	Inve	ntors	ship S	Statement					

If the named inventors are each not the inventors of all the claims an explanation, including the ownership WARNING: of the various claims at the time the last claimed invention was made, should be submitted.

-				Claims as Filed	•						
	Α.	₩	Regular Application								
10.	Fee	Calcu	ulation (37 CFR 1.16)								
NOTE:	applie entitl	This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.									
NOTE:		_	application forming the basis 5(a) and 1.63.	for the claim for priority must be	referred to in the oath or declaration						
			will follow.								
			is attached.								
		fr	om which priority is cla	imed							
			Country	Appln. No.	Filed						
	Cert	ified	copy of application								
9.	Cert	ified	Сору								
WARNI	NG:			UNDER 37 CFR 3.73(b)" must Notice of April 30, 1993. 1150	be filed when a continuation-in-par O.G. 62-64.						
			ignment." Notice of May 4, 1:								
NOTE:	"If an			v application, send two separate le	tters—one for the application and on						
		⋈	will follow.	•							
					ASSIGNMENT (DOCUMENT or □ FORM PTO 1595 is also						
	abla	An a	assignment of the inventi	on to COUNCIL OF SCIENTIF	FIC & INDUSTRIAL RESEARCH						
8.	Assi	gnme	ent								
			the attached translatio	n is a verified translation. 3	7 CFR 1.52(d).						
		_	-English								
	1.69 ☑		ନ୍ଧା. English								
NOTE:			ish oath or declaration in the	form provided or approved by the	РТО need not be translated, 37 CF						
NOTE:	Englis	An application including a signed oath or declaration may be filed in a language other than English. A verification of the non-English language application and the processing fee of \$130.00 required by 37 Cm 1.17(k) is required to be filed with the application or within such time as may be set by the Office, 37 Cm 1.50(m).									
7.	Lang	guage									
			the same. An explanati the last claimed invent		o of the various claims at th						
		The	same								
	The	inver	ntorship for all the claim	is in this application are:							

Number Filed						N	lumb	er E	Extra Rate			Basic Fee 37 CFR 1.16(a) \$690.00
Total Claims 5 (37 CFR 1.16(c))				5	- 20	=		0	x	\$	18.00	
Indepe (37 C				1	- 3	=		0	х	\$	78.00	
Multip (37 C			ent claim(s)))	, if a	iny				+	\$	260.00	
		Am	endment ca	ncel	ling ex	tra cla	aims	enc	lose	d.		
		Am	endment de	letin	ıg mult	iple-d	epend	den	cies	enc	losed.	
		Fee	for extra c	aims	s is not	bein	g paid	d at	this	s tim	ne.	
NOTE:	men	t, prio		ion o	f the tim	e perio	d set f	•		•		cancelled by amend- d Trademark Office
							Filir	ng F	ee (Calc	ulation \$	
В.			ign applicat 10.00 — 3		R 1.16	i(f))	Filir	ng F	ee (Calc	ulation \$	
C.			nt applicatio 80.00 — 3		R 1.16	i(g))	Filir	ng F	ee (Calc	ulation \$	
11.	Sma	all En	tity Statem	ent(s	s)							
		Ver	ified Statem er 37 CFR	nent((s) that							
		Filir	ng Fee Calcu	ulatio	on (50°	(50% of A , B or C above)					\$	
NOTE:	•		s of the full fed onths of the d	•								nd request are filed
12.	Req		for Internat	iona	l-Type	Searc	ch (37	7 C	FR 1	1.10	4(d)) <i>(Comp</i>	lete, if applica-
	Please prepare an international-type search report for this application at the time when national examination on the merits takes place.											
13.	Fee Payment Being Made At This Time											
	\square	Not	Enclosed									
		Ø	No filing f by 37 CFI									urcharge required
		Enc	losed									
			basic filing	g fee	•						\$	

			h)) (See attached "COVE ENT ACCOMPANYING N	
		For processing an applia non-English language (\$130.00; 37 CFR 1.52		on in
		Processing and retentio (\$130.00; 37 CFR 1.53		
		Fee for international-typ (\$40.00; 37 CFR 1.21(\$
NOTE:	failing to co CFR 1.53 a basic filing	1(I) establishes a fee for proce implete the application pursuar nd 1.78, indicate that in order fee must be paid or the proces otification under §53(d).	nt to 37 CFR 1.53(d) and this, to obtain the benefit of a prior	as well as the changes to 37 U.S. application, either the
			Total fees enclosed	\$
14.	Method o	of Payment of Fees		
	☐ Che	ck in the amount of	\$	
	☐ Chai	rge Account No. 12-042	5 in the amount of	\$
	A du	uplicate of this transmitte	al is attached.	
NOTE:		l be itemized in such a manner	that it is clear for which purpo	ose the fees are paid. 37 CFR
15. Aut	<i>1.22(b).</i> horization	to Charge Additional Fe	es	
WARNING: WARNING:	Accurately	are to be paid on filing, the for y count claims, especially mult ges are authorized.		mpleted. d unexpected high charges, if extra
		-		owing additional fees by this to Account No. 12-0425.
	□ 37	CFR 1.16(a), (f) or (g) (filing fees)	
	□ 37	CFR 1.16(b), (c) and (d)	(presentation of extra c	laims)
only by th	be paid or the PTO in an	hese claims cancelled by ame	ndment prior to the expiration CFR 1.16(d)), it might be best	filing or on later presentation must of the time period set for response not to authorize the PTO to charge inal action.
		1.16(e) (surcharge for f in the filing date of the a		and/or declaration on a date
	37 CFR	1.17 (application proces	sing fees)	
WARNING:	should be 1,136(a) i	made only with the knowledge	that: "Submission of the approp	under §1.136(a), this authorization priate extension fee under 37 C.F.R. led." (Emphasis added). Notice of

		37 CFR 1.18 (issue fee at or before CFR 1.311(b))	mailing of Notice of Allowance, pursuant to	37									
NOTE:	Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notic of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notic of allowance. 37 CFR 1.311(b).												
NOTE:	the ap	37 CFR 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application prior to paying, or at the time of paying, issue fee". From the wording of 37 CFR 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.											
16.	Instr	ructions As To Overpayment											
		credit Account No. 12-0425											
		refund	Janes Signature of Attorney										
Reg. No	33	3 778	Janet I. Cord										
,og. 11	J. 00	5,7	Ladas & Parry										
Γel. No	. (21	12) 708-1935	26 West 61 Street New York, NY 10023										
	Inco	orporation by reference of added page	s										
		of prior U.S. application(s) (inclusion) stage as a continuation, division	e application in this transmittal claims the bending an international application entering the Unal or C-I-P application) and complete and attempted and TRANSMITTAL WHERE BENEFIT (LAIMED)	I.S. ach									
		Plus Added Pages for New Applicatio tion(s) Claimed	n Transmittal Where Benefit of Prior U.S. Appl	ica-									
			Number of pages added										
		Plus Added Pages for Papers Referre	ed to in Item 4 Above										
			Number of pages added	t									
		Plus "Assignment Cover Letter Acco	empanying New Application"										
			Number of pages added										
Z	Statement Where No Further Pages Added												
		(If no further pages form a part of the page and check the following item:)	is Transmittal, then end this Transmittal with	this									
	NZI	This transmittal ends with this page											